Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
idiotype single-chain variable fragment vaccine
- Development stage
- Unknown
- Lead developer
- Large Scale Biology
- Modality
- Vaccines & Immunotherapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
The idiotype single-chain variable fragment (scFv) vaccine is a patient-specific active immunotherapy developed for the treatment of follicular B-cell lymphoma. Produced using a transient plant-virus expression system (Tobacco Mosaic Virus vector), the vaccine consists of the recombinant VH and VL domains of the patient's unique tumor-specific immunoglobulin (idiotype). Unlike traditional idiotype vaccines that require complex hybridoma-based production and chemical coupling to carrier proteins like keyhole limpet haemocyanin (KLH), this scFv subunit design is intended to simplify manufacturing and rapidly induce a polyclonal, tumor-specific immune response. In clinical trials, it has been administered subcutaneously, often in conjunction with the adjuvant GM-CSF, to stimulate both humoral and cellular anti-tumor immunity by targeting the unique B-cell receptor idiotype present on the surface of malignant B cells.
- Other names
- scFv idiotype vaccineplant-produced scFv vaccineidiotype scFv vaccineplant-produced scFv idiotype vaccine
02
Targets
Id (Tumor-specific idiotype immunoglobulin)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on idiotype single-chain variable fragment vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on idiotype single-chain variable fragment vaccine.